Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention (Review)

Oncology Letters

Volumn 5, Issue 4, 2013, Pages 1087-1092

  Hamid, Abdu Selim ^a   Tesfamariam, Saias Goitom ^b   Zhang, Yucheng ^a   Zhang, Zhen Gui ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

Aflatoxin B1; Chemopreventive agents; Dietary changes; DNA adducts; Hepatocellular carcinoma; Interventions

Indexed keywords

AFLATOXIN B1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A; OPUNTIA EXTRACT; PHENETHYL ISOTHIOCYANATE;

AFLATOXICOSIS; ARTICLE; CARCINOGEN DNA INTERACTION; CHEMOPROPHYLAXIS; COFFEE; DIET; DISEASE ASSOCIATION; FOOD INTAKE; GEOGRAPHIC DISTRIBUTION; GRAPEFRUIT; HUMAN; LIVER CELL CARCINOMA; LIVER INJURY; NONHUMAN;

EID: 84874410090     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1169     Document Type: Article

References (66)

1. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
2. Lord R, Suddle A and Ross PJ: Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. Int J Clin Pract 65: 182-188, 2011
3. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
5. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
6. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009
7. Nguyen MH, Whittemore AS, Garcia RT, et al: Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2: 820-824, 2004.
8. Farazi PA and DePinho RA: Hepatocellular carcinoma patho genesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006.
9. Ward E, Jemal A, Cokkinides V, et al: Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54: 78-93, 2004.
10. McCracken M, Olsen M, Chen MS Jr, et al: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57: 190-205, 2007.
11. Röcken C and Carl-McGrath S: Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 19: 269-278, 2001.
12. McGlynn KA and London WT: Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19: 3-23, 2005.
13. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25: 143-154, 2005.
14. London WT, Evans AA, McGlynn K, et al: Viral, host and environmental risk factors for hepatocellular carcinoma: a prospective study in Haimen City, China. Intervirology 38: 155-161, 1995.
15. Chen CJ, Yu MW and Liaw YF: Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 12: S294-S308, 1997.
16. Madden CR, Finegold MJ and Slagle BL: Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J Virol 76: 11770-11774, 2002.
17. Li Y, Su JJ, Qin LL, Yang C, Ban KC and Yan RQ: Synergistic effect of hepatitis B virus and aflatoxin B1 in hepatocarcino genesis in tree shrews. Ann Acad Med Singapore 28: 67-71, 1999.
18. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A and Castagnetta LA: Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann NY Acad Sci 963: 13-20, 2002.
19. Groopman JD, Scholl P and Wang JS: Epidemiology of human aflatoxin exposures and their relationship to liver cancer. Prog Clin Biol Res 395: 211-222, 1996.
20. Baydar T, Engin AB, Girgin G, Aydin S and Sahin G: Aflatoxin and ochratoxin in various types of commonly consumed retail ground samples in Ankara, Turkey. Ann Agric Environ Med 12: 193-197, 2005.
21. Bennett JW and Klich M: Mycotoxins. Clin Microbiol Rev 16: 497-516, 2003.
22. Fink-Gremmels J: Mycotoxins: their implications for human and animal health. Vet Q 21: 115-120, 1999.
23. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM and Aggarwal D: Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 80: 1106-1122, 2004.
24. McLean M and Dutton MF: Cellular interactions and metabolism of aflatoxin: an update. Pharmacol Ther 65: 163-192, 1995.
25. Wang JS, Huang T, Su J, et al: Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 10: 143-146, 2001.
26. Mardani M, Rezapour S and Rezapour P: Survey of aflatoxins in Kashkineh: A traditional Iranian food. Iran J Microbiol 3: 147-151, 2011.
27. Banerjee S, Brown KL, Egli M and Stone MP: Bypass of aflatoxin B1 adducts by the Sulfolobus solfataricus DNA polymerase IV. J Am Chem Soc 133: 12556-12568, 2011.
28. Obuseh FA, Jolly PE, Kulczycki A, et al: Aflatoxin levels, plasma vitamins A and E concentrations, and their association with HIV and hepatitis B virus infections in Ghanaians: a cross-sectional study. J Int AIDS Soc 14: 53, 2011.
29. Lewis L, Onsongo M, Njapau H, et al: Aflatoxin contamination of commercial maize products during an outbreak of acute aflatoxicosis in eastern and central Kenya. Environ Health Perspect 113: 1763-1767, 2005.
30. Oyelami OA, Maxwell SM and Adeoba E: Aflatoxins and ochratoxin A in the weaning food of Nigerian children. Ann Trop Paediatr 16: 137-140, 1996.
31. Egal S, Hounsa A, Gong YY, et al: Dietary exposure to aflatoxin from maize and groundnut in young children from Benin and Togo, West Africa. Int J Food Microbiol 104: 215-224, 2005.
32. Kpodo K, Thrane U and Hald B: Fusaria and fumonisins in maize from Ghana and their co-occurrence with aflatoxins. Int J Food Microbiol 61: 147-157, 2000.
33. Awuah RT and Kpodo KA: High incidence of Aspergillus flavus and aflatoxins in stored groundnut in Ghana and the use of a microbial assay to assess the inhibitory effects of plant extracts on aflatoxin synthesis. Mycopathologia 134: 109-114, 1996.
34. Sugimura T: Nutrition and dietary carcinogens. Carcinogenesis 21: 387-395, 2000.
35. Sutandyo N: Nutritional carcinogenesis. Acta Med Indones 42: 36-42, 2010.
36. Sharma RA and Farmer PB: Biological relevance of adduct detection to the chemoprevention of cancer. Clin Cancer Res 10: 4901-4912, 2004.
37. Martin J and Dufour JF: Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol 14: 1720-1733, 2008.
38. Jackson PE, Kuang SY, Wang JB, et al: Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 24: 1657-1663, 2003.
39. Bressac B, Kew M, Wands J and Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431, 1991.
40. Montesano R, Hainaut P and Wild CP: Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 89: 1844-1851, 1997.
41. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ and Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428, 1991.
42. Ozturk M: p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338: 1356-1359, 1991.
43. Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ and Taylor JA: Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 10: 617-625, 2001.
44. Nogueira JA, Ono-Nita SK, Nita ME, et al: 249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. BMC Cancer 9: 204, 2009.
45. Wang JS and Groopman JD: DNA damage by mycotoxins. Mutat Res 424: 167-181, 1999.
46. Eaton DL and Gallagher EP: Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 34: 135-172, 1994.
47. Gallagher EP, Kunze KL, Stapleton PL and Eaton DL: The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol Appl Pharmacol 141: 595-606, 1996.
48. Ilic Z, Crawford D, Vakharia D, Egner PA and Sell S: Glutathione-;S-transferase A3 knockout mice are sensitive to acute cytotoxic and genotoxic effects of aflatoxin B1. Toxicol Appl Pharmacol 242: 241-246, 2010.
49. Dash B, Afriyie-Gyawu E, Huebner HJ, et al: Determinants of the variability of aflatoxin-albumin adduct levels in Ghanaians. J Toxicol Environ Health A 70: 58-66, 2007.
50. Eaton DL, Bammler TK and Kelly EJ: Interindividual differences in response to chemoprotection against aflatoxin-induced hepatocarcinogenesis: implications for human biotransformation enzyme polymorphisms. Adv Exp Med Biol 500: 559-576, 2001.
51. Kirk GD, Turner PC, Gong Y, et al: Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev 14: 373-379, 2005.
52. Smela ME, Currier SS, Bailey EA and Essigmann JM: The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 22: 535-545, 2001.
53. Wild CP and Turner PC: The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 17: 471-481, 2002.
54. Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H and Langouët S: Activation and detoxication of aflatoxin B1. Mutat Res 402: 121-128, 1998.
55. Sabbioni G, Skipper PL, Büchi G and Tannenbaum SR: Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 8: 819-824, 1987.
56. Anand P, Kunnumakkara AB, Sundaram C, et al: Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25: 2097-2116, 2008.
57. Wild CP and Hall AJ: Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 462: 381-393, 2000.
58. Gescher AJ, Sharma RA and Steward WP: Cancer chemopre vention by dietary constituents: a tale of failure and promise. Lancet Oncol 2: 371-379, 2001.
59. Brahmi D, Bouaziz C, Ayed Y, Ben Mansour H, Zourgui L and Bacha H: Chemopreventive effect of cactus Opuntia ficus indica on oxidative stress and genotoxicity of aflatoxin B1. Nutr Metab (Lond) 8: 73, 2011.
60. Peterson S, Lampe JW, Bammler TK, Gross-Steinmeyer K and Eaton DL: Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food Chem Toxicol 44: 1474-1484, 2006.
61. Miyata M, Takano H, Guo LQ, Nagata K and Yamazoe Y: Grapefruit juice intake does not enhance but rather protects against aflatoxin B1-induced liver DNA damage through a reduction in hepatic CYP3A activity. Carcinogenesis 25: 203-209, 2004.
62. Cavin C, Marin-Kuan M, Langou ët S, et al: Induction of Nrf2- mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver. Food Chem Toxicol 46: 1239-1248, 2008.
63. Gross-Steinmeyer K, Stapleton PL, Tracy JH, Bammler TK, Strom SC and Eaton DL: Sulforaphane and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression. Toxicol Sci 116: 422-432, 2010.
64. Sotomayor RE, Washington M, Nguyen L, Nyang'anyi R, Hinton DM and Chou M: Effects of intermittent exposure to aflatoxin B1 on DNA and RNA adduct formation in rat liver: dose-response and temporal patterns. Toxicol Sci 73: 329-338, 2003.
65. McGlynn KA, Hunter K, LeVoyer T, et al: Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 63: 4594-4601, 2003.
66. Turner PC, Sylla A, Gong YY, et al: Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet 365: 1950-1956, 2005.